Sanofi to publish COVID-19 vaccine price in development with GSK after Phase I/II trial results

Company is expected to release the results from the Phase I/II clinical trials this month

  
The logo of Sanofi is seen at the company's headquarters in Paris, France, April 24, 2020.

The logo of Sanofi is seen at the company's headquarters in Paris, France, April 24, 2020.

REUTERS/Charles Platiau

PARIS - French drug maker Sanofi will announce the price of the potential COVID-19 vaccine it is developing with Britain's GlaxoSmithKline after it has released Phase I/II results of the trials, vaccines chief Thomas Triomphe said on Thursday.

The company is expected to release the results from the Phase I/II clinical trials this month.

It is also developing a vaccine with U.S. biotech firm Translate Bio, with clinical human trials expected to start this month.

(Reporting by Matthias Blamont in Paris; Writing by Josephine Mason in London; Editing by Jon Boyle) ((Josephine.Mason@thomsonreuters.com; +44 207 542 7695; Reuters Messaging: josephine.mason.reuters.com@reuters.net))

More From Business